Is UNCY or ACTU more profitable?

Unicycive Therapeutics' return on equity of -134.69% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -134.69% -84.51% Actuate Therapeutics N/A -430.93% -180.86%

Is GNLX or ACTU more profitable?

Genelux's return on equity of -174.55% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -174.55% -123.65% Actuate Therapeutics N/A -430.93% -180.86%

Do analysts rate SPRO or ACTU?

Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has better valuation and earnings, ENLV or ACTU?

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A

Is ENLV or ACTU more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Enlivex Therapeutics N/A 248.08% 206.39% Actuate Therapeutics N/A -430.93% -180.86%

Actuate Therapeutics (ACTU) Competitors

$1.52 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$1.57 +0.05 (+3.29%)

As of 07/2/2026 07:59 PM Eastern

Compare

ACTU vs. COYA, UNCY, GNLX, SPRO, and ENLV

Should you buy Actuate Therapeutics stock or one of its competitors? MarketBeat compares Actuate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Actuate Therapeutics include Coya Therapeutics (COYA), Unicycive Therapeutics (UNCY), Genelux (GNLX), Spero Therapeutics (SPRO), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical products" industry.

How does Actuate Therapeutics compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations, media sentiment and institutional ownership.

In the previous week, Coya Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Coya Therapeutics and 0 mentions for Actuate Therapeutics. Coya Therapeutics' average media sentiment score of 0.50 beat Actuate Therapeutics' score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Coya Therapeutics	Positive
Actuate Therapeutics	Neutral

Actuate Therapeutics has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Coya Therapeutics presently has a consensus target price of $15.33, indicating a potential upside of 161.66%. Actuate Therapeutics has a consensus target price of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' higher possible upside, analysts clearly believe Actuate Therapeutics is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Coya Therapeutics has higher revenue and earnings than Actuate Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.29	-$21.23M	-$1.15	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Coya Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Summary

Coya Therapeutics beats Actuate Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Unicycive Therapeutics had 43 more articles in the media than Actuate Therapeutics. MarketBeat recorded 43 mentions for Unicycive Therapeutics and 0 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 0.00 beat Unicycive Therapeutics' score of -0.20 indicating that Actuate Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Actuate Therapeutics	Neutral

Actuate Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	230.80	-$26.56M	-$2.21	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Unicycive Therapeutics currently has a consensus price target of $27.40, suggesting a potential upside of 378.18%. Actuate Therapeutics has a consensus price target of $17.50, suggesting a potential upside of 1,051.32%. Given Actuate Therapeutics' higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Unicycive Therapeutics' return on equity of -134.69% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Actuate Therapeutics	N/A	-430.93%	-180.86%

40.4% of Unicycive Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Summary

Unicycive Therapeutics beats Actuate Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Genelux presently has a consensus target price of $18.00, suggesting a potential upside of 502.01%. Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 1,051.32%. Given Actuate Therapeutics' higher probable upside, analysts clearly believe Actuate Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Genelux had 4 more articles in the media than Actuate Therapeutics. MarketBeat recorded 4 mentions for Genelux and 0 mentions for Actuate Therapeutics. Genelux's average media sentiment score of 0.20 beat Actuate Therapeutics' score of 0.00 indicating that Genelux is being referred to more favorably in the media.

Company	Overall Sentiment
Genelux	Neutral
Actuate Therapeutics	Neutral

Genelux's return on equity of -174.55% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-174.55%	-123.65%
Actuate Therapeutics	N/A	-430.93%	-180.86%

37.3% of Genelux shares are held by institutional investors. 7.5% of Genelux shares are held by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Actuate Therapeutics has lower revenue, but higher earnings than Genelux. Genelux is trading at a lower price-to-earnings ratio than Actuate Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	13,407.16	-$32.15M	-$0.85	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Genelux has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market.

Summary

Genelux beats Actuate Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Actuate Therapeutics compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends and analyst recommendations.

25.6% of Spero Therapeutics shares are owned by institutional investors. 2.9% of Spero Therapeutics shares are owned by company insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Spero Therapeutics has a beta of 1.49, indicating that its stock price is 49% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market.

Actuate Therapeutics has a consensus price target of $17.50, indicating a potential upside of 1,051.32%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Spero Therapeutics had 2 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Spero Therapeutics and 0 mentions for Actuate Therapeutics. Spero Therapeutics' average media sentiment score of 0.30 beat Actuate Therapeutics' score of 0.00 indicating that Spero Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Spero Therapeutics	Neutral
Actuate Therapeutics	Neutral

Spero Therapeutics has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Spero Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$54.77M	2.33	$8.57M	$0.24	9.17
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

Spero Therapeutics has a net margin of 24.90% compared to Actuate Therapeutics' net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Summary

Spero Therapeutics beats Actuate Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Actuate Therapeutics compare to Enlivex Therapeutics?

Enlivex Therapeutics (NASDAQ:ENLV) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

Enlivex Therapeutics has a beta of 1.52, suggesting that its stock price is 52% more volatile than the broader market. Comparatively, Actuate Therapeutics has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Enlivex Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A

In the previous week, Enlivex Therapeutics' average media sentiment score of 0.00 equaled Actuate Therapeutics'average media sentiment score.

Company	Overall Sentiment
Enlivex Therapeutics	Neutral
Actuate Therapeutics	Neutral

1.0% of Enlivex Therapeutics shares are owned by institutional investors. 12.3% of Enlivex Therapeutics shares are owned by insiders. Comparatively, 58.0% of Actuate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Enlivex Therapeutics' return on equity of 248.08% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enlivex Therapeutics	N/A	248.08%	206.39%
Actuate Therapeutics	N/A	-430.93%	-180.86%

Enlivex Therapeutics currently has a consensus target price of $16.50, suggesting a potential upside of 3,027.37%. Actuate Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 1,051.32%. Given Enlivex Therapeutics' higher probable upside, equities research analysts clearly believe Enlivex Therapeutics is more favorable than Actuate Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Enlivex Therapeutics beats Actuate Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Actuate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ACTU vs. The Competition

Export

Metric	Actuate Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.37M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-1.57	21.61	28.02	24.70
Price / Sales	N/A	340.19	540.37	99.46
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	4.47	8.66	10.96	6.46
Net Income	-$22.23M	$23.81M	$3.57B	$337.01M
7 Day Performance	-9.52%	3.39%	2.12%	1.69%
1 Month Performance	-19.15%	10.81%	5.25%	3.81%
1 Year Performance	-76.70%	62.61%	33.29%	23.90%

Actuate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ACTU Actuate Therapeutics	1.7965 of 5 stars	$1.52 flat	$17.50 +1,051.3%	-76.7%	$36.37M	N/A	N/A	10	Gap Down
COYA Coya Therapeutics	2.3881 of 5 stars	$5.72 -2.3%	$15.33 +168.3%	-6.5%	$134.07M	$7.95M	N/A	6
UNCY Unicycive Therapeutics	3.2652 of 5 stars	$4.86 +3.5%	$27.40 +464.4%	+23.6%	$132.29M	$680K	N/A	9	Trending News Analyst Forecast Options Volume Analyst Revision Gap Down High Trading Volume
GNLX Genelux	1.8932 of 5 stars	$2.92 -3.0%	$18.00 +516.2%	+0.3%	$131.07M	$10K	N/A	10	News Coverage Gap Down
SPRO Spero Therapeutics	1.5614 of 5 stars	$2.25 +1.6%	N/A	-24.4%	$129.99M	$66.80M	9.35	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ACTU) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Actuate Therapeutics (ACTU) Competitors

ACTU vs. COYA, UNCY, GNLX, SPRO, and ENLV

How does Actuate Therapeutics compare to Coya Therapeutics?

Summary

How does Actuate Therapeutics compare to Unicycive Therapeutics?

Summary

How does Actuate Therapeutics compare to Genelux?

Summary

How does Actuate Therapeutics compare to Spero Therapeutics?

Summary

How does Actuate Therapeutics compare to Enlivex Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Actuate Therapeutics (ACTU) Competitors

ACTU vs. COYA, UNCY, GNLX, SPRO, and ENLV

How does Actuate Therapeutics compare to Coya Therapeutics?

Does the media refer more to COYA or ACTU?

Is COYA or ACTU more profitable?

Do analysts prefer COYA or ACTU?

Do institutionals and insiders believe in COYA or ACTU?

Which has higher earnings & valuation, COYA or ACTU?

Which has more volatility & risk, COYA or ACTU?

Summary

How does Actuate Therapeutics compare to Unicycive Therapeutics?

Does the media refer more to UNCY or ACTU?

Which has preferable earnings and valuation, UNCY or ACTU?

Do analysts prefer UNCY or ACTU?

Is UNCY or ACTU more profitable?

Do insiders and institutionals hold more shares of UNCY or ACTU?

Which has more risk and volatility, UNCY or ACTU?

Summary

How does Actuate Therapeutics compare to Genelux?

Do analysts prefer GNLX or ACTU?

Does the media refer more to GNLX or ACTU?

Is GNLX or ACTU more profitable?

Do institutionals and insiders believe in GNLX or ACTU?

Which has higher valuation and earnings, GNLX or ACTU?

Which has more volatility & risk, GNLX or ACTU?

Summary

How does Actuate Therapeutics compare to Spero Therapeutics?

Do insiders & institutionals have more ownership in SPRO or ACTU?

Which has more risk and volatility, SPRO or ACTU?

Do analysts rate SPRO or ACTU?

Does the media favor SPRO or ACTU?

Which has preferable earnings & valuation, SPRO or ACTU?

Is SPRO or ACTU more profitable?

Summary

How does Actuate Therapeutics compare to Enlivex Therapeutics?

Which has more volatility and risk, ENLV or ACTU?

Which has better valuation and earnings, ENLV or ACTU?

Does the media favor ENLV or ACTU?

Do insiders & institutionals hold more shares of ENLV or ACTU?

Is ENLV or ACTU more profitable?

Do analysts prefer ENLV or ACTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACTU vs. The Competition

Actuate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools